View Older Stories View More Recent Stories

Apr 12, 2024 08:01AM Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives
Mar 26, 2024 08:01AM Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
Feb 28, 2024 05:10PM Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update
Jan 4, 2024 08:01AM Portage Biotech (PRTG) to pause further drug development in the PORT-2 iNKT program
Jan 4, 2024 08:00AM Portage Biotech Reports Business and Strategic Update
Nov 28, 2023 04:01PM Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update
Nov 6, 2023 08:01AM Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
Sep 20, 2023 08:00AM Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference
Sep 5, 2023 08:00AM Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors
Aug 30, 2023 08:00AM Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business Update
Jul 31, 2023 04:05PM Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update
Jun 26, 2023 08:00AM Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors
Jun 5, 2023 08:00AM Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American S
Jun 1, 2023 08:00AM Portage Biotech to Participate in Panel Discussion During the 2023 BIO International Conference
Apr 26, 2023 05:00PM Portage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Mar 7, 2023 08:00AM Portage Biotech to Present at Oppenheimer’s 33rd Annual Healthcare Conference
Mar 1, 2023 08:00AM Portage Biotech Announces Results for Fiscal Quarter Ended December 31, 2022
Feb 27, 2023 04:05PM Portage Biotech Hosting Key Opinion Leader Event on Targeting the Adenosine Pathway in Cancer
Feb 15, 2023 08:00AM Portage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership Summit
Nov 29, 2022 04:43PM Portage Biotech Announces Results for Fiscal Quarter Ended September 30, 2022
Nov 10, 2022 09:00AM Portage Biotech Presents Updated Data on the Phase 1/2 Trial Evaluating PORT-2 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
Nov 8, 2022 08:02AM Portage Biotech (PRTG) Announces Clinical Trial Collaboration Agreement with Merck (MRK)
Nov 8, 2022 08:00AM Portage Biotech Announces Clinical Trial Collaboration Agreement with Merck
Oct 3, 2022 01:01PM Pfizer Completes Acquisition of Biohaven Pharmaceuticals
Sep 14, 2022 08:40AM Portage Biotech (PRTG) Issues Research and Development Update
Sep 14, 2022 08:39AM Portage Biotech Provides Research and Development Update
Sep 8, 2022 08:00AM Portage Biotech to Present at Upcoming Investor Conferences
Aug 29, 2022 08:00AM Portage Biotech Announces Results for Fiscal Quarter Ended June 30, 2022
Aug 18, 2022 08:05AM Portage Biotech (PRTG) announces Dr. Ian Walters, CEO, will be appointed Chairman
Aug 18, 2022 08:00AM Portage Biotech Announces Leadership Updates
Aug 1, 2022 09:10AM UPDATE -- Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022
Aug 1, 2022 08:00AM Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022
Jul 20, 2022 09:03AM Portage Biotech (PRTG) Acquires Remaining 22% Stake in Invariant Natural Killer T cell (iNKT) Agonist Platform
Jul 20, 2022 09:00AM Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform
Jul 6, 2022 04:05PM Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway
Jul 6, 2022 01:00PM Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven’s Troriluzole and Vigeo’S VT1021 in GBM AGILE Trial
Jun 6, 2022 08:00AM Portage Biotech Summarizes Data Presented at ASCO 2022 Annual Meeting Including Updates from Ongoing PORT-2 Study
May 10, 2022 06:45AM Pfizer to Acquire Biohaven Pharmaceuticals
Apr 27, 2022 06:45AM Pfizer (PFE) and Biohaven’s (BHVN) VYDURA Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine
Apr 27, 2022 06:45AM Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine
Apr 25, 2022 08:05AM Portage Biotech (PRTG) Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity
Apr 25, 2022 08:00AM Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity
Apr 13, 2022 10:00AM Portage Biotech Highlights Promising Data Presented on STING-Activating Therapy, PORT-5 (STI-001) at AACR 2022 Annual Meeting
Mar 31, 2022 08:00AM Portage Biotech Provides Update on Clinical-Stage and Development Programs
Mar 9, 2022 09:00AM Portage Biotech Announces Presentation of PORT-5 (STI-001) Late-Breaking Data at AACR 2022 Annual Meeting
Feb 25, 2022 07:00AM Biohaven Pharma (BHVN) Pfizer (PFE) Receive Positive CHMP Opinion for Migraine Treatment
Feb 25, 2022 06:59AM Biohaven and Pfizer Receive Positive CHMP Opinion for Migraine Treatment
Feb 24, 2022 05:43PM Portage Biotech Announces Financial Results and Provides Business Update for Third Quarter of 2022 Fiscal Year
Feb 15, 2022 08:00AM Portage Biotech Announces New Appointments to its Management Team and Board of Directors
Feb 14, 2022 07:01AM Biohaven Pharma (BHVN), Pfizer (PFE) Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea
View More Recent Stories View Older Stories